Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline

Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C financing round. This capital infusion will accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV).